Cellectis (Paris:ALCLS), the genome engineering specialist, has
announced the completion of a structurally important transaction
concerning its subsidiary Cellectis bioresearch, which specializes in
designing, developing and marketing products and services essentially
for academic and biopharmaceutical industry researchers: a simplified
legal structure, with Ectycell merged into Cellectis bioresearch; and a
reinforced equity position, with a €3.5 million contribution subscribed
for by Caisse des DÉpÔts.
Ectycell’s tie-up with Cellectis bioresearch will enable Cellectis
bioresearch to enrich and sustain its offering, synergistically
combining the technologies of targeted gene editing and iPS cell-derived
The new structure has the advantage of being more uniform with the aim
of providing disruptive innovations that run the gamut from in vitro
genetic diversity control for R&D to client-specific turnkey solutions.
As part of this rationalization process, the Cellectis Group plans to
bring together the activities of Cellectis bioresearch and Ectycell at a
single production facility.
On December 30, 2013, all of Ectycell’s shares were contributed to
Cellectis bioresearch, which also carried out a capital increase of
€3.5 million euros in cash, fully subscribed for by Caisse des DÉpÔts,
in accordance with the commitments made under the partnership initiated
in January 2012.
Following these transactions, Cellectis now holds 75.5% of the share
capital of Cellectis bioresearch, while Caisse des DÉpÔts holds 24.5%.
A stronger equity position was essential to reinforcing Cellectis
bioresearch’s autonomy and its capacity for innovation in a competitive
environment where major players based in the United States and Japan
tend to hold sway.
This investment reflects the priority placed by the Caisse des DÉpÔts
group, as a privileged partner of French state and local authorities, on
helping SMEs raise capital and foster innovation. Caisse des DÉpÔts
initiated this investment under the convention signed with the French
state in 2008 to support Innovation Platforms in line with public policy
on competitiveness clusters.
Founded in Paris in 1999, the Cellectis
Group bases its work on highly specific DNA engineering technologies.
Its application sectors are human health, agriculture and bio-energies.
Cellectis was co-founded by AndrÉ Choulika, its Chairman and CEO, and
David Sourdive, Executive Vice President of Corporate Development, and
is now one of the world’s top companies in the field of genome
engineering, with revenue of €21 million in 2012. Leading the field of
pluripotent stem cells, Cellectis has developed expertise in drug
discovery, toxicity testing, and regenerative medicine.
has signed more than 100 industry agreements with pharmaceutical,
agrochemical, and biotechnology companies. The Group’s clients and
partners include University College London (UCL), the National
Institutes of Health (NIH), Novo Nordisk, the Center for iPS Cell
Research and Application (CiRA) of Kyoto University, AFM, Novartis,
BASF, Bayer, and Limagrain. Since 2007, Cellectis has been listed on the
NYSE Euronext Alternext market (code: ALCLS) in Paris.
information, visit our website: www.cellectis.com.
About the Caisse des DÉpÔts group
Caisse des DÉpÔts,
together with its subsidiaries, is a French state financial institution
serving as a long-term investor in support of the public interest and
local economic development. Its mandate was reaffirmed by the Economic
Modernization Act (LME) of August 4, 2008.
This press release and the information contained
herein do not constitute an offer to sell or subscribe, or a
solicitation of an offer to buy or subscribe, for shares in Cellectis in
Philippe Valach, +33 (0)1 81
69 16 00
des DÉpÔts group
Claude Schneegans, +33 (0)1 49 55 68 58